Actively Recruiting

Age: 18Years +
All Genders
NCT06906367

A Study of Patients With Fabry Disease (US Specific)

Led by Amicus Therapeutics · Updated on 2026-04-28

450

Participants Needed

8

Research Sites

328 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

CONDITIONS

Official Title

A Study of Patients With Fabry Disease (US Specific)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years or older with Fabry disease and amenable GLA variants
  • Migalastat-treated patients who started treatment within 24 months before enrollment with eGFR ≥ 30 mL/min/1.73 m2 and are currently taking migalastat
  • Patients showing decline in Fabry disease symptoms including decreased eGFR, microalbuminuria/macroalbuminuria, proteinuria, or males with classic Fabry disease phenotype
  • Migalastat-treated patients from prior clinical trials exposed to treatment for at least 24 months with eGFR ≥ 30 mL/min/1.73 m2 and still on migalastat
  • Untreated patients with amenable GLA variants, eGFR ≥ 30 mL/min/1.73 m2, and meeting local treatment guidelines
  • ERT-treated patients who started within 24 months before enrollment, with eGFR ≥ 30 mL/min/1.73 m2 and amenable GLA variants
  • All participants must be able to understand and provide written informed consent or assent
Not Eligible

You will not qualify if you...

  • Patients currently participating in a clinical trial of any investigational medicinal product or device at the time of enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

UAB Nephrology Research Clinic at Paula Building

Birmingham, Alabama, United States, 35233

Not Yet Recruiting

2

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

Actively Recruiting

3

Emory Genetics

Atlanta, Georgia, United States, 30322

Actively Recruiting

4

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Not Yet Recruiting

5

New York-Presbyterian Morgan Stanley Children's Hospital - Columbia University Medical Center

New York, New York, United States, 10032

Not Yet Recruiting

6

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15224

Not Yet Recruiting

7

Renal Disease Research Institute

Dallas, Texas, United States, 75204

Actively Recruiting

8

Lysosomal and Rare Disorders Research and Treatment Center, Inc.

Fairfax, Virginia, United States, 22030

Actively Recruiting

Loading map...

Research Team

A

Amicus Therapeutics Patient Advocacy

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here